CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-01 | Russo Rene PRESIDENT AND CEO | Option exercise · Restricted Stock Units | −44,250 | 88,500 | ||
| 2025-12-31 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +451,885 | 451,885 | ||
| 2025-12-31 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) 10b5-1 | +95,221 | 95,221 | ||
| 2025-12-31 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) 10b5-1 | +668,789 | 668,789 | ||
| 2025-12-31 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +1,500,258 | 1,500,258 | ||
| 2025-11-26 | GILEAD SCIENCES, INC. 10% owner | Option exercise · Prefunded Warrants (right to buy) | +13,335,000 | $0.75 | $10.0M | 36,645,266 |
| 2025-11-26 | GILEAD SCIENCES, INC. 10% owner | Option exercise · Series B Warrants (right to buy) | −13,335,000 | 0 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +131,700 | 131,700 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Returned to the company · Stock Option (right to buy) | −55,000 | 0 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Returned to the company · Stock Option (right to buy) | −25,000 | 0 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Returned to the company · Stock Option (right to buy) | −20,000 | 0 | ||
| 2025-11-21 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +625,000 | 625,000 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Returned to the company · Stock Option (right to buy) | −44,210 | 0 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +44,210 | 44,210 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Returned to the company · Stock Option (right to buy) | −15,000 | 0 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2025-11-21 | Luptakova Katarina CHIEF MEDICAL OFFICER | Returned to the company · Stock Option (right to buy) | −35,000 | 0 |
Page 2 of 12 · 224 trades